CAR-T therapy for renal cell carcinoma gains fast track approval

Joining the strong number of cancer therapies being approved in 2023 is the CAR-T cell therapy from Invectys, the clinical-stage immuno-oncology company.
Invectys focuses on developing novel therapies for advanced cancers, and their latest therapy is no exception, using revolutionary technology to target HLA-G, an immune checkpoint and tumour-specific antigen that is often overlooked.
The HLA-G molecule is normally only expressed during pregnancy, with the purpose of protecting the foetus from the mother’s immune system. In cancer however, tumours can commandeer HLA-G to create a protected environment for them to thrive in, guarding against the natural immune system, allowing them to grow uninhibited.
The new product, IVS-3001, has been granted Fast Track Designation from the US FDA, for use in patients with HLA-G positive locally advanced or metastatic clear cell renal cell carcinoma (RCC) who have previously failed or are intolerant to pre-existing RCC therapies. The therapy is an autologous CAR-T therapy, forged from the patient’s own cells, modified to target HLA-G-bearing cells and will work to boost the body’s natural defences, enabling it to better fight against cancerous growth. The approval will aid in progressing cancer therapeutics, increasing options for patients, and ultimately leading to improved patient outcomes.
Fast Track designation is granted to revolutionary treatments aiming to fulfil an unmet need in serious medical conditions, in this case, HLA-G positive locally advanced or metastatic clear cell renal cell carcinoma that has been unresponsive to treatment. IVS-3001 is the first CAR-T therapy to be approved for RCC treatment.
The Fast Track designation for IVS-3001 was based on compelling data from the submission from Invectys to the Investigational New Drug Application (IND). Data is being collected from a Phase I/IIa clinical trial into solid tumours (NCT05672459) started in June 2023, with support from the MD Anderson and the Cell Therapy Manufacturing Centre (CTMC) for the development of the therapy.
“We are thrilled to receive the FDA’s Fast Track designation for IVS-3001,” commented Jake Kushner, CEO of Invectys. “This recognition further validates the potential of our CAR-T cell therapy in revolutionising cancer treatment for patients with solid tumours. The dedicated team at Invectys, as well as our partners, are committed to bringing this innovative therapy to the clinic and making a meaningful difference in the lives of cancer patients.”
Sources:
Pharmaceutical Technology. FDA fast-tracks Invectys’ CAR-T therapy for renal cell carcinoma. [Date Accessed 02/08/2023].
Invectys Cancer Immunotherapeutics. FDA Grants Fast Track designation to IVS-3001, a CAR-T Cell Therapy in the Treatment of Renal Cell Carcinoma. Date Accessed [02/08/2023].
Related News
-
News Merck invests US$1 billion in new USA-based vaccine facility
Merck annouces the opening of a new state-of-the-art vaccine production plant in Durham, North Carolina, USA, in efforts to bring pharmaceutical product development onto home soil in face of new import tariffs. -
News US FDA adds haemodialysis bloodlines to devices shortage list
On March 14, 2025, the US FDA published an open letter to healthcare providers citing continuing supply disruptions of haemodialysis bloodlines, an essential component of dialysis machines. -
News Women in Pharma: Manufacturing personal and team success
Our monthly Women in Pharma series highlights the influential lives and works of impactful women working across the pharmaceutical industry, and how the industry can work towards making the healthcare industry and workplace more equitable and inclusive... -
News The next 15 drugs up for negotiation with Medicare include several blockbusters
By now, everyone is quite familiar with the drug price negotiations taking place between drug companies and the Centres for Medicare & Medicaid Services (CMS) in the USA as part of measures being taken to reduce the cost of drugs for patients, to make ... -
News Pfizer may shift production back to US under Trump pharma tariffs
At the 45th TD Cowen annual healthcare conference in Boston, USA, Pfizer CEO Albert Bourla outlined the potential for Pfizer to shift its overseas drug manufacturing back to the US as pharmaceutical industry players weigh their options against Presiden... -
News Experimental drug for managing aortic valve stenosis shows promise
The new small molecule drug ataciguat is garnering attention for its potential to manage aortic valve stenosis, which may prevent the need for surgery and significantly improve patient experience. -
News Trump's federal funding shift could stifle biotech innovation
Over a month into the second term of Donald Trump’s presidency and we have already seen some big changes affecting the healthcare industry. -
News Sanofi receives FDA warning over contamination at manufacturing site
The FDA issues a warning letter to Sanofi over contamination violations found at the Framingham biologics facility, in Boston, MA, USA.
Recently Visited
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance